CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen - PubMed (original) (raw)
CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen
J Hernández et al. J Immunol. 2001.
Abstract
p53 is an attractive target for cancer immunotherapy because it is overexpressed in a high proportion of many different types of tumors. However, it is also expressed in normal tissues and acts as a toleragen in vivo. Previously, detailed examination of the repertoire specific for the murine p53(261-269) epitope in conventional and p53-deficient mice demonstrated that because of expression of p53, the CD8(+) T cells that respond to this epitope express low-affinity TCRs. It has been reported that tolerance to tumor Ags can be broken by in vivo administration of anti-CTLA-4 mAb. With the goal of overriding tolerance and achieving optimal activation of p53-specific CTL, the current study has assessed the effect of anti-CTLA-4 mAb on the p53-specific repertoire. It was found that blockade of CTLA-4 engagement at the time of antigenic stimulation induced a vigorous amplification of the CTL responses to p53 as well as proportionate expansion of the memory T cell pool. This effect was dependent on the presence of CD4(+) T cell help and correlated with an enhancement of helper function. However, anti-CTLA-4 treatment did not enhance the avidity of the resultant p53-specific CTL populations and, therefore, could not reverse this important consequence of tolerance.
Similar articles
- Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoé K. Ito D, et al. J Immunol. 2000 Feb 1;164(3):1230-5. doi: 10.4049/jimmunol.164.3.1230. J Immunol. 2000. PMID: 10640735 - CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD. Espenschied J, et al. J Immunol. 2003 Mar 15;170(6):3401-7. doi: 10.4049/jimmunol.170.6.3401. J Immunol. 2003. PMID: 12626601 - Strategies for tumor elimination by cytotoxic T lymphocytes.
Sherman LA, Theobald M, Morgan D, Hernandez J, Bacik I, Yewdell J, Bennink J, Biggs J. Sherman LA, et al. Crit Rev Immunol. 1998;18(1-2):47-54. doi: 10.1615/critrevimmunol.v18.i1-2.60. Crit Rev Immunol. 1998. PMID: 9419447 Review. - Targeting p53, hdm2, and CD19: vaccination and immunologic strategies.
Voss RH, Lotz C, Cellary A, Theobald M. Voss RH, et al. Bone Marrow Transplant. 2000 May;25 Suppl 2:S43-5. doi: 10.1038/sj.bmt.1702353. Bone Marrow Transplant. 2000. PMID: 10933187 Review.
Cited by
- Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, Santollani L, Kennedy A, Rothschilds AM, Spranger S, Sansom DM, Wittrup KD. Lax BM, et al. Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2300895120. doi: 10.1073/pnas.2300895120. Epub 2023 Jul 24. Proc Natl Acad Sci U S A. 2023. PMID: 37487077 Free PMC article. - Immune Infiltration Landscape in Lung Squamous Cell Carcinoma Implications.
Zhao J, Bao W, Cai W. Zhao J, et al. Biomed Res Int. 2020 Oct 10;2020:5981870. doi: 10.1155/2020/5981870. eCollection 2020. Biomed Res Int. 2020. PMID: 33102584 Free PMC article. - Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer.
Liu W, Zhang L, Xiu Z, Guo J, Wang L, Zhou Y, Jiao Y, Sun M, Cai J. Liu W, et al. Onco Targets Ther. 2020 Jul 27;13:7229-7241. doi: 10.2147/OTT.S255491. eCollection 2020. Onco Targets Ther. 2020. PMID: 32801752 Free PMC article. Review. - p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, Yen Y, Espenschied J, Ellenhorn JD, Diamond DJ, Chung V. Hardwick NR, et al. Clin Cancer Res. 2014 Sep 1;20(17):4459-70. doi: 10.1158/1078-0432.CCR-13-3361. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987057 Free PMC article. Clinical Trial. - Association between CTLA-4 60G/A and -1661A/G polymorphisms and the risk of cancers: a meta-analysis.
Yan Q, Chen P, Lu A, Zhao P, Gu A. Yan Q, et al. PLoS One. 2013 Dec 23;8(12):e83710. doi: 10.1371/journal.pone.0083710. eCollection 2013. PLoS One. 2013. PMID: 24376736 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous